Wegener Granulomatosis

• EMA withdrawal · 2026-08-21
  EMA Revoked: Tavneos (avacopan) — Vifor Fresenius Medical Care Renal Pharma France

  The EMA revoked Tavneos (avacopan) for its indications, including Microscopic Polyangiitis and Wegener Granulomatosis, effective January 15,…

• EMA withdrawal · 2026-08-19
  EMA Revoked: Tavneos (avacopan) — Vifor Fresenius Medical Care Renal Pharma France

  The EMA revoked Tavneos (avacopan) authorization for indications including Microscopic Polyangiitis and Wegener Granulomatosis.

• EMA withdrawal · 2021-08-16
  EMA Withdrawn: Ritemvia (rituximab) — Celltrion Healthcare Hungary Kft.

  EMA withdrawal of Ritemvia (rituximab) by Celltrion Healthcare Hungary Kft., affecting indications in lymphoma (non-Hodgkin) and vasculitic …

• EMA withdrawal · 2019-07-08
  EMA Withdrawn: Rituzena (previously Tuxella) (rituximab) — Celltrion Healthcare Hungary Kft.

  EMA withdrew Rituzena (rituximab) from the market (formerly Tuxella), with the decision dated 28 January 2019.

• EMA withdrawal · 2008-06-19
  EMA Application withdrawn: Spanidin (gusperimus trihydrochloride) — Euro Nippon Kayaku GmbH

  EU application for Spanidin (gusperimus trihydrochloride) withdrawn; previously targeted Wegener Granulomatosis (granulomatosis with polyang…

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.